Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug

Stock Track

04/09

LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.

The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.

Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1152091097"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152091097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152091097?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152091097","market":"nz","top_or_hot":-1,"title":"Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug","media":"Stock Track","content":"<p>LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.</p><p>The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.</p><p>Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LEADS BIOLABS-B Soars 5.06% Intraday on Positive Phase II Clinical Trial Results for Biliary Tract Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-09 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.</p><p>The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.</p><p>Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1152091097","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152091097","pubTimestamp":1775699209,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.The company announced that the preliminary safety evaluation for the Phase II...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"个股追踪|胆道癌药物II期临床试验结果积极领涨BIOLABS-B盘中大涨5.06%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B's stock surged 5.06% during intraday trading following encouraging updates from a key clinical trial.The company announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. The data indicated a good overall safety profile and tolerability, with no new safety signals identified, and preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage.Based on these favorable safety and efficacy results, the project has smoothly progressed into the expansion phase, with the first patient already enrolled, accelerating the drug's development timeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}